Advertisement

November 19, 2026

VOYAGER CE Begins for Abbott’s Encantor Software-Guided Balloon-Expandable TAVR System

KEY TAKEAWAYS

  • Abbott has initiated VOYAGER CE to evaluate its investigational Encantor software-guided, balloon-expandable TAVR system.
  • The prospective, single-arm study will enroll up to 300 patients with symptomatic severe aortic stenosis in Europe and Australia.
  • Study findings are intended to support regulatory submissions in Europe and Australia, with a United States pivotal trial also planned.

November 19, 2026—Abbott announced it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of the company’s investigational Encantor transcatheter aortic valve replacement (TAVR) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. Stephen Worthley, MBBS, led the first enrollment in the VOYAGER CE study at Macquarie University in Sydney, Australia.

According to the company, the prospective, single-arm, premarket study will be conducted in Europe and Australia. It will enroll up to 300 patients with symptomatic severe aortic stenosis caused by severe calcium buildup in the aortic valve. VOYAGER CE will be the basis to seek approval for use in Europe and Australia.

Didier Tchétché, MD, who serves as Coprincipal Investigator of VOYAGER CE, commented on the device in Abbott’s press release.

“TAVR has transformed the treatment of severe aortic stenosis, but physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients,” stated Dr. Tchétché, who is Director of the Structural Heart Disease Department at Clinique Pasteur in Toulouse, France. “Encantor’s balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence.”

Abbott noted that findings from the early feasibility study of Encantor supported initiation of the VOYAGER CE study. The 6-month data on safety, hemodynamic, and functional outcomes from the Encantor early feasibility study and an overview of the Encantor TAVR system will be presented during an innovation session on November 22 at the PCR London Valves 2026 conference.

The Encantor balloon-expandable TAVR system is available for investigational use only and not for use anywhere in the world. Abbott plans to initiate a pivotal trial in the United States in the coming months, stated the press release.

Advertisement


November 19, 2026

FDA Clears Siemens Healthineers Syngo.CT Coronary Cockpit Software


)